Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02879357
Other study ID # 2014P000211
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2014
Est. completion date December 2017

Study information

Verified date October 2019
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis of the Serious Illness Care Program (SICP) is that adherence to the Serious Illness Conversation Guide (SICG) portion, the SIGC, will enhance patient understanding and allow control over their own decisions, relieve burdens of decision-making on family members, and help patients achieve a state of peace as they approach the end of life.


Description:

The aim of the Serious Illness Care Program (SICP) is to provide clinicians with an evidence-based structure for eliciting and documenting vital information about preferences for patient driven care of their serious illness. It is designed to help open the door for patients, families, and clinicians to talk and reflect on end-of-life issues in an ongoing way. The hypothesis of the Serious Illness Care Program is that adherence to the conversation guide portion, the SIGC, will enhance patient understanding and allow control over their own decisions, relieve burdens of decision-making on family members, and help patients achieve a state of peace as they approach the end of life. For this protocol specifically, the investigators are testing a pilot intervention of a quality improvement project; the investigators plan to train clinicians and assess the feasibility and impact of the Serious Illness Care Program, which includes patient identification, clinician training, "triggering" of clinicians to conduct the SICG conversation, and documentation, in the iCMP at the Brigham and Women's Hospital.


Recruitment information / eligibility

Status Completed
Enrollment 194
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Clinician Inclusion Criteria:

1. Brigham and Women's Hospital or Newton Wellesley Primary Care Clinician at one of the following practices: The Phyllis Jen Center for Primary Care, Faulkner Community Physicians, Brigham and Women's Physician Group, Brigham & Women's Primary Care Associates of Brookline, Brigham Circle Medical Associates, Faulkner

2. Care for patients enrolled in Brigham and Women's Hospital integrated Care Management Program (iCMP)

Clinician Exclusion Criteria:

1. Resident in Training

2. Non-English Speaking Clinic (e.g. Spanish Clinic)

Patient Inclusion Criteria:

1. Over 18 years of age

2. English Speaker

3. Patient at Brigham and Women's Hospital or Newton Wellesley Primary Care Clinician at one of the following practices: The Phyllis Jen Center for Primary Care, Faulkner Community Physicians, Brigham and Women's Physician Group, Brigham & Women's Primary Care Associates of Brookline, Brigham Circle Medical Associates, Faulkner

4. Enrolled in Brigham and Women's Hospital integrated Care Management Program

Patient Exclusion Criteria:

1. Patient at Dana-Farber Cancer Institute

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Training
Clinician training System for patient selection System of "triggering" and tracking conversations Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values Longitudinal Medical Record (LMR) documentation module to serve as a "Single source of truth" about advance care preferences in the LMR.

Locations

Country Name City State
United States Brigham and Women's Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Brigham and Women's Hospital Partners HealthCare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Completion of eligible conversations Median percentage of eligible patients with completed conversations (will report for all intervention clinicians as a whole and also on individual clinician level) from date of clinician training study start to study end date, assessed for up to 18 months
Other Length of conversation Median length of time per conversation in the intervention group as reported by clinician survey from date of clinician training study start to study end date, assessed for up to 18 months
Other Clinician Confidence Clinicians who are trained to use the Guide will have improved confidence in carrying out end-of-life conversations, compared to untrained clinicians. Confidence will be evaluated before training and at end of study and measured using a 22-question survey asking clinicians to quantify their confidence on a scale of 1-7. This survey was designed by study investigators based on national surveys used to evaluate a sample of medical students, residents, and attending physicians' attitudes about end-of-life care, as well as the Harvard Medical School Center for Palliative Care's national faculty development program. at initial clinician training and end of study (an average of 18 months)
Other Clinician Attitudes Clinicians who are trained to use the Guide will have improved attitudes in carrying out end-of-life conversations, compared to untrained clinicians. Confidence will be evaluated before training and at end of study and measured using an 11-question survey asking clinicians to quantify their confidence on a scale of 1-5. This survey was designed by study investigators based on national surveys used to evaluate a sample of medical students, residents, and attending physicians' attitudes about end-of-life care, as well as the Harvard Medical School Center for Palliative Care's national faculty development program. at clinician training and end of study (an average of 18 months)
Other Utilization Patients of clinicians who are trained to use the Guide will have higher rates of hospice usage, less health care utilization, and lower expenses near the end of life. We will measure utilization outcomes for those patients for whom we have claims data through risk contracts and the accountable care organization and will compare usage and trends between intervention and comparison patients. at end of study (an average of 18 months)
Primary Percentage of eligible patients with documented goals of care conversations For patients whose death falls during the study period, the percentage of goals of care conversations completed and documented in the electronic medical record by clinicians in the intervention group and the control group. A completed conversation is defined by key elements being documented regarding goals of care in the patient's medical record. from date of determination of eligibility to date of death death during the study period, assessed for up to 18 months
Secondary Median number of days before death of first documented goals of care conversation For all patients whose death falls during the study period, the median number of days from the date of the first documented goals of care conversation to date of death in both the intervention and the control group. from date of determination of eligibility to date of death during the study period, assessed for up to 18 months
Secondary Percentage of eligible patients with more comprehensive documentation of goals of care before death For all patients whose death falls during the study period, the percentage of patients with more comprehensive goals of care documentation before death in both the intervention group and the control group. More comprehensive is defined as documentation of a goals of care conversation that addresses more than code status only and will be evaluated for completeness in containing more key elements of a Serious Illness Care Guide conversation. from date of determination of eligibility to date of death during study period, assessed for up to 18 months
See also
  Status Clinical Trial Phase
Completed NCT05333133 - High Calorie Formula Intervention on Weight, Length Increment, Total Lymphocyte Counts, TNF-alpha and IGF-1 in Failure to Thrive Children N/A
Completed NCT05289674 - The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection N/A
Completed NCT03202576 - Nasogastric Tube Securement Comparison Study N/A
Completed NCT01338363 - Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists N/A
Completed NCT04393909 - Improving Safety of Diagnosis and Therapy in the Inpatient Setting N/A
Not yet recruiting NCT01772927 - Clinical Tolerance of Numeta 13% N/A
Completed NCT02128984 - Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children N/A
Completed NCT01070173 - Ghrelin Levels in Children With Poor Growth N/A
Completed NCT00483691 - Trial of Home Visitation Among Infants With Failure To Thrive N/A
Completed NCT00190658 - Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome Phase 3
Completed NCT02647580 - Appetite Regulation in Children With Failure to Thrive N/A
Recruiting NCT01314989 - Cyproheptadine as an Appetite Stimulant Phase 4
Completed NCT00001639 - Evaluation of Patients With Unresolved Chromosome Abnormalities N/A
Completed NCT04985227 - Impact of Home Weight Tele-monitoring on the Number of Office Visits in the First Six Weeks of Life in Infants. N/A
Terminated NCT02589132 - Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive N/A
Terminated NCT02710383 - Biomarker for Cystic Fibrosis
Completed NCT00325611 - Multidisciplinary Inpatient Palliative Care Intervention N/A